1Research Center for Preclinical and Clinical Medicine, Health Research Organization, National Research and Innovation Agency (BRIN), Cibinong, West Java, Indonesia
2Faculty of Medicine, President University, Jababeka, Cikarang, West Java, Indonesia
3Research Center for Biomedical, Health Research Organization, National Research and Innovation Agency (BRIN), Cibinong, West Java, Indonesia
4Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
5Indonesian Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
6Department of Medical Pharmacy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
7PT Riseta Medica Inovasia, Jakarta, Indonesia
Aging is characterized by progressive molecular and cellular dysfunction, including chronic low-grade inflammation, oxidative stress, endothelial impairment, and reduced regenerative capacity [1-3]. These interrelated processes have stimulated growing interest in genetic therapeutics, particularly microRNAs (miRNAs), because they can modulate multiple pathogenic pathways simultaneously [4-12]. However, nucleic-acid-based anti-aging interventions remain constrained by poor physicochemical stability, rapid nuclease degradation, insufficient cellular uptake, and inefficient intracellular release [13-21]. Drug delivery systems are therefore essential for translating genetic anti-aging strategies into practical therapeutics. Among non-viral platforms, liposomes remain highly attractive because of their biocompatibility, compositional flexibility, cargo-protective capacity, and pharmaceutical scalability [13-21]. This focused review discusses the role of liposome-based systems in the delivery of genetic materials for anti-aging applications, with particular emphasis on miRNA-mediated modulation of inflammaging (i.e., chronic low-grade age-associated inflammation), endothelial dysfunction, and regenerative decline [1-12]. Special attention is given to miR-146a, miR-21, and miR-126 because of their relevance to NF-κB signaling, PI3K/AKT-mediated survival, and vascular homeostasis [7-12,25-31]. The review also compares liposomes with other nucleic-acid carriers, including lipid nanoparticles, polymeric systems, and extracellular vesicles, and highlights translational issues such as formulation stability, endosomal escape, tissue targeting, and safety [13-24]. Overall, liposome-based carriers represent a practical and promising platform for advancing precision anti-aging therapeutics in regenerative medicine.
Keywords: Anti-aging therapy; inflammaging; microRNA delivery; liposome; nucleic acid therapeutics; nanocarrier; regenerative medicine; endothelial dysfunction.
How to cite this article: Purwoko RY, Rinendyaputri R, Idaiani S, Pawitan JA, Purwaningsih EH, Krisnamurti DGB, Fachri W, Saputra S. Liposome-Based Delivery of Genetic Materials for Anti-Aging Therapy: A Focused Review of microRNA-Oriented Translational Strategies. Int J Drug Deliv Technol. 2026;16(15s): 772-778. DOI: 10.25258/ijddt.16.15s.86
Source of support: Nil.
Conflict of interest: None